Abstract
The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance. The efficacy and safety of the drug has been well established in these patient populations. Acarbose shows no weakening of efficacy in long-term diabetes treatment, reduces the development of type 2 diabetes in those with impaired glucose tolerance, and also appears to reduce the risk of cardiovascular disease. The underlying mechanisms of its effect on the risk of developing macrovascular complications have still to be elucidated. The mode of action of acarbose, which precedes all other metabolic processes involved in blood glucose regulation, inhibits high increases in postprandial blood glucose. Due to this early mode of action, acarbose also modifies insulin and proinsulin secretion which are both involved in ß-cell dysfunction and insulin resistance and may be independent risk factors for cardiovascular mortality. Based on the literature available the present state of knowledge on insulin and proinsulin as risk factors for cardiovascular mortality is reviewed as well as the effect of acarbose on the regulation of the ß-cells as monotherapy and in combination regimens. Possible associated interactions with the cardiovascular system are identified.
Keywords: Acarbose, Proinsulin, Serum insulin, ß-cell function, Cardiovascular disease
Current Diabetes Reviews
Title: Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Volume: 5 Issue: 3
Author(s): Christoph Rosak and Gabriele Mertes
Affiliation:
Keywords: Acarbose, Proinsulin, Serum insulin, ß-cell function, Cardiovascular disease
Abstract: The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance. The efficacy and safety of the drug has been well established in these patient populations. Acarbose shows no weakening of efficacy in long-term diabetes treatment, reduces the development of type 2 diabetes in those with impaired glucose tolerance, and also appears to reduce the risk of cardiovascular disease. The underlying mechanisms of its effect on the risk of developing macrovascular complications have still to be elucidated. The mode of action of acarbose, which precedes all other metabolic processes involved in blood glucose regulation, inhibits high increases in postprandial blood glucose. Due to this early mode of action, acarbose also modifies insulin and proinsulin secretion which are both involved in ß-cell dysfunction and insulin resistance and may be independent risk factors for cardiovascular mortality. Based on the literature available the present state of knowledge on insulin and proinsulin as risk factors for cardiovascular mortality is reviewed as well as the effect of acarbose on the regulation of the ß-cells as monotherapy and in combination regimens. Possible associated interactions with the cardiovascular system are identified.
Export Options
About this article
Cite this article as:
Rosak Christoph and Mertes Gabriele, Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System, Current Diabetes Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339909788920910
DOI https://dx.doi.org/10.2174/157339909788920910 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Mechanisms Linking Leptin to Arterial and Venous Thrombosis: Potential Pharmacological Targets
Current Pharmaceutical Design Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
Current Drug Metabolism Mechanisms for Antiplatelet Action of Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Current Topics in Medicinal Chemistry Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) Blood Pressure Variability and Mortality in end Stage Renal Disease
Current Hypertension Reviews Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Preventive Effect of Soybean on Brain Aging and Amyloid-β Accumulation: Comprehensive Analysis of Brain Gene Expression
Recent Patents on Food, Nutrition & Agriculture MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Cyanosis Due to Methemoglobinemia Induced by Topical Anesthesia in a Premature Infant
Current Drug Therapy Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Disease Modifying Osteoarthritis Drugs: Facing Development Challenges and Choosing Molecular Targets
Current Drug Targets CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology
Current Gene Therapy Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Effects of Intravenous Apo A-I, HDLs and Apo A-I/Phospholipid Discs on Vascular Metabolism and Atherosclerosis in Animals and Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Hypothyroidism and Atherosclerosis-Possible Implication of the Renin-Angiotensin System
Current Hypertension Reviews